骨康胶囊辅助经皮椎体后凸成形术治疗骨质疏松性椎体压缩性骨折临床研究

Clinical Study on Gukang Capsules in Assisting Percutaneous Kyphoplasty to Treat Osteoporotic Vertebral Compression Fractures

目的:观察骨康胶囊辅助经皮椎体后凸成形术(PKP)治疗骨质疏松性椎体压缩性骨折(OVCF)的临床疗效及其对骨代谢的影响。方法:将78例OVCF患者随机分为治疗组与对照组各39例。对照组给予PKP治疗,治疗组在对照组的基础上加用骨康胶囊治疗。比较2组临床疗效及不良反应发生情况,以及2组治疗前后血清骨代谢指标[骨钙素(OC)、骨密度(BMD)、Ca^(2+)(钙离子)]、炎症指标[一氧化氮(NO)、肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)]水平。结果:治疗组总有效率为97.44%,对照组为79.49%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组OC、Ca^(2+)、BMD水平比较,差异无统计学意义(P>0.05)。治疗后,对照组OC、Ca^(2+)、BMD水平与治疗前比较无明显变化(P>0.05);治疗组OC、Ca^(2+)、BMD水平均较治疗前升高(P<0.05),且明显高于对照组(P<0.05)。治疗前,2组NO、TNF-α、IL-6水平比较,差异无统计学意义(P>0.05);治疗后,2组NO、TNF-α、IL-6水平均较治疗前降低(P<0.05),且治疗组NO、TNF-α、IL-6水平均低于对照组(P<0.05)。治疗组不良反应发生率为7.69%,对照组为10.25%,2组比较,差异无统计学意义(P>0.05)。结论:骨康胶囊联合PKP治疗OVCF可明显提高临床疗效,促进骨密度增长,改善骨代谢和骨质疏松程度,减轻炎症反应,且不良反应相对较少。

Objective:To observe the clinical effect of Gukang Capsules in assisting percutaneous kyphoplasty(PKP)to treat osteoporotic vertebral compression fractures(OVCF)and its influence on bone metabolism.Methods:A total of 78 OVCF patients were randomly divided into the treatment group and the control group,with 39 patients in each group.The control group was treated with PKP,and the treatment group was additionally treated with Gukang Capsules based on the treatment of the control group.The clinical effects and occurrence of adverse reactions between the two groups were compared,and the levels of bone metabolic indexes,including serum osteocalcin(OC),bone mineral density(BMD)and Ca^(2+),and inflammatory indexes,including serum nitric oxide(NO),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6),were also compared between the two groups before and after treatment.Results:The total effective rate was 97.44% in the treatment group and 79.49% in the control group,the difference being significant(P<0.05).Before treatment,there was no significant difference in the levels of OC,Ca^(2+)and BMD between the two groups(P>0.05).After treatment,the levels of OC,Ca^(2+)and BMD in the control group had no significant changes when compared with those before treatment(P>0.05);the levels of OC,Ca^(2+)and BMD in the treatment group were increased when compared with those before treatment(P<0.05),and significantly higher than those in the control group(P<0.05).Before treatment,there was no significant difference in the levels of NO,TNF-α and IL-6 between the two groups(P>0.05).After treatment,the levels of NO,TNF-α and IL-6 in both groups were decreased when compared with those before treatment(P<0.05),and the levels of NO,TNF-α and IL-6 in the treatment group were lower than those in the control group(P<0.05).The incidence of adverse reactions was 7.69% in the treatment group and 10.25% in the control group,there being no significant difference between the two groups(P>0.05).Conclusion:The therapy of Gukang Capsules combined with PKP in the treatment of OVCF can significantly improve the clinical effect,promote the increase of bone density,enhance bone metabolism and osteoporosis,and reduce inflammation,with relatively few adverse reactions.